GLP-1-Agonisten, eine Klasse von Gewichtsverlustmedikamenten, können das Risiko von Herzpatienten für den frühen Tod halbieren, studiert die Studie
https://www.theguardian.com/society/2025/aug/31/weight-loss-drugs-can-halve-heart-patients-risk-of-early-death-study-finds
2 Kommentare
Weight loss drugs mimic the glucagon-like peptide (GLP) 1 hormone, which makes people feel full, and were initially developed to treat diabetes. In recent years evidence has emerged suggesting they could prove to be lifesaving across a range of conditions beyond obesity.
Now the results of major new research, presented at the European Society of Cardiology annual conference, show weight loss drugs could reduce the risk of people with heart conditions being hospitalised or dying early by as much as 58%.
In the study, US researchers from Mass General Brigham, a nonprofit network of doctors and hospitals headquartered in Boston, analysed real-world data from more than 90,000 heart failure patients who were obese and had type 2 diabetes. All had heart failure with preserved ejection fraction (HFpEF), the most common form of the condition.
The results showed those taking semaglutide were 42% less likely to end up in hospital or die prematurely, compared with a proxy for placebo. In the same study, tirzepatide cut the risk of hospitalisation for heart failure or death from any cause by 58%.
Globally, more than 60 million people have heart failure. Previous studies have suggested that weight-loss drugs may improve heart failure symptoms, but their effect on important outcomes such as hospitalisation and death has never been evaluated in large populations until now.